135 related articles for article (PubMed ID: 16507651)
1. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted.
Pitas G; Laurenzana EM; Williams DK; Owens SM; Gentry WB
Drug Metab Dispos; 2006 Jun; 34(6):906-12. PubMed ID: 16507651
[TBL] [Abstract][Full Text] [Related]
2. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody.
Laurenzana EM; Gunnell MG; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2003 Sep; 306(3):1092-8. PubMed ID: 12829731
[TBL] [Abstract][Full Text] [Related]
3. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.
Proksch JW; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2000 Mar; 292(3):831-7. PubMed ID: 10688594
[TBL] [Abstract][Full Text] [Related]
4. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum.
Proksch JW; Gentry WB; Owens SM
Drug Metab Dispos; 2000 Jul; 28(7):742-7. PubMed ID: 10859146
[TBL] [Abstract][Full Text] [Related]
5. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats.
Valentine JL; Arnold LW; Owens SM
J Pharmacol Exp Ther; 1994 Jun; 269(3):1079-85. PubMed ID: 8014850
[TBL] [Abstract][Full Text] [Related]
6. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats.
McClurkan MB; Valentine JL; Arnold L; Owens SM
J Pharmacol Exp Ther; 1993 Sep; 266(3):1439-45. PubMed ID: 8371148
[TBL] [Abstract][Full Text] [Related]
7. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
Valentine JL; Owens SM
J Pharmacol Exp Ther; 1996 Aug; 278(2):717-24. PubMed ID: 8768723
[TBL] [Abstract][Full Text] [Related]
8. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats.
Hardin JS; Wessinger WD; Wenger GR; Proksch JW; Laurenzana EM; Owens SM
J Pharmacol Exp Ther; 2002 Jul; 302(1):119-26. PubMed ID: 12065708
[TBL] [Abstract][Full Text] [Related]
9. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.
Kalinichev M; Robbins MJ; Hartfield EM; Maycox PR; Moore SH; Savage KM; Austin NE; Jones DN
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):414-22. PubMed ID: 17945407
[TBL] [Abstract][Full Text] [Related]
10. Phencyclidine dependence: the relationship of dose and serum concentrations to operant behavioral effects.
Wessinger WD; Owens SM
J Pharmacol Exp Ther; 1991 Jul; 258(1):207-15. PubMed ID: 2072296
[TBL] [Abstract][Full Text] [Related]
11. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
Valentine JL; Mayersohn M; Wessinger WD; Arnold LW; Owens SM
J Pharmacol Exp Ther; 1996 Aug; 278(2):709-16. PubMed ID: 8768722
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.
Pentel PR; Dufek MB; Roiko SA; Lesage MG; Keyler DE
J Pharmacol Exp Ther; 2006 May; 317(2):660-6. PubMed ID: 16407464
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat.
Proksch JW; Gentry WB; Owens SM
J Pharmacol Exp Ther; 1998 Nov; 287(2):616-24. PubMed ID: 9808688
[TBL] [Abstract][Full Text] [Related]
15. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms.
Wass C; Archer T; Pålsson E; Fejgin K; Klamer D; Engel JA; Svensson L
Behav Brain Res; 2006 Jul; 171(1):147-53. PubMed ID: 16677724
[TBL] [Abstract][Full Text] [Related]
16. Continuous intravenous infusion of phencyclidine in unrestrained rats results in the rapid induction of tolerance and physical dependence.
Spain JW; Klingman GI
J Pharmacol Exp Ther; 1985 Aug; 234(2):415-24. PubMed ID: 4040569
[TBL] [Abstract][Full Text] [Related]
17. Effects of gestational exposure to phencyclidine: distribution and neurochemical alterations in maternal and fetal brain.
Ali SF; Ahmad G; Slikker W; Bondy SC
Neurotoxicology; 1989; 10(3):383-92. PubMed ID: 2576301
[TBL] [Abstract][Full Text] [Related]
18. Neonatal NMDA receptor antagonist treatments have no effects on prepulse inhibition of postnatal day 25 Sprague-Dawley rats.
Boctor SY; Ferguson SA
Neurotoxicology; 2009 Jan; 30(1):151-4. PubMed ID: 19038286
[TBL] [Abstract][Full Text] [Related]
19. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine.
Gozzi A; Schwarz A; Crestan V; Bifone A
Magn Reson Imaging; 2008 Sep; 26(7):999-1006. PubMed ID: 18486387
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
Hardin JS; Wessinger WD; Proksch JW; Owens SM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1113-22. PubMed ID: 9618414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
